Trinity Capital (TRIN) announced the commitment of $30M in growth capital to Iantrek, a medical technology company and a leader in the bio-interventional ophthalmic surgery space. Iantrek develops minimally invasive surgical technologies designed to treat chronic eye diseases, particularly glaucoma, aimed at restoring the eye’s natural fluid outflow pathways and reducing ocular pressure. Its technology includes instrumentation and biologic tissue solutions that seek to help enable micro-interventional procedures for improved patient outcomes.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIN:
- Trinity Capital provides $50M in capital to Cala Health
- Trinity Capital Announces Strong Q1 2026 Investment Activity
- Trinity Capital participates in a conference call with Clear Street
- Trinity Capital provides $50M in growth capital to Sage Health
- Trinity Capital management to meet virtually with Citizens